Summarized by Masters of Longevity from Nature - Main.
A late-stage trial found pelacarsen did not lower cardiovascular events despite cutting Lp(a).
Key Takeaways
- Pelacarsen failed to reduce heart attacks and strokes.
- The drug markedly reduced Lp(a) levels by about 80% or more.
- Other firms have ongoing trials testing different Lp(a) approaches.
